Alkem Laboratories Launches 'Reliever Free India' Initiative with 600-700 Camps Nationwide
Written by Arushi Sharma
Alkem Laboratories unveils its "Reliever Free India" initiative, aiming to transform asthma management by advocating for controller medications. Through 600-700 camps across India, the campaign educates on the importance of preventive care for better asthma control and improved patient outcomes.
In observance of World Asthma Day 2024, Alkem Laboratories (Alkem) has unveiled plans to conduct 600 to 700 camps across India, in collaboration with nearly 100 hospitals in tier-1 and tier-2 cities, as part of its "Reliever Free India" initiative.
This nationwide campaign, initiated in 2023, aims to revolutionize asthma management by advocating for a shift from reliance on reliever medications to the importance of controller medications.
Reliever medications provide immediate relief during asthma symptoms by opening up the airways, while controller medications are taken regularly to prevent asthma symptoms and reduce inflammation. Building on the success of its inaugural year, Alkem is intensifying its efforts in the second year of the campaign.
Asthma affects an estimated 262 million individuals globally, leading to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. Despite advancements in medical treatment, asthma remains a significant challenge for patients and healthcare providers.
A spokesperson from Alkem stated, "We have engaged with over 500 camps since the inception of our campaign. This year, we are expanding our commitment by organizing at least 600 camps and clinics to raise awareness about asthma and its management. Our goal is to empower patients with the knowledge they need to take control of their health."
The "Reliever Free India" campaign underscores the importance of using controller medications for optimal asthma management. While reliever medications offer immediate relief during asthma attacks, they do not address the underlying inflammation that contributes to the chronic nature of the condition. Over-reliance on relievers can lead to poor long-term outcomes and increased risk of exacerbations.
Through this initiative, Alkem aims to educate patients, healthcare professionals, and the general public about the benefits of controller medications in preventing asthma symptoms and reducing the need for rescue medication. This concerted effort reflects Alkem's commitment to improving asthma care and fostering a healthier future for individuals living with the condition.